Remetinostat

Remetinostat - for the treatment of skin cancers

Remetinostat is a topical histone deacetylase (HDAC) inhibitor for use in non-melanoma skin cancers with phase II data in MF-CTCL, basal cell carcinoma and squamous cell carcinoma, having shown positive clinical efficacy and acceptable tolerability without systemic side effects. The unique design of remetinostat enables topical application, with activity only in the skin. As soon as remetinostat reaches the blood stream, it is degraded, avoiding the side effects associated with other HDAC inhibitors.

In 2025, remetinostat was outlicensed to Biossil, Inc, for global, exclusive development rights. Biossil is a Toronto-based AI-native drug developer focused on developing novel therapies for heterogenous diseases with urgent unmet medical needs.

The terms of the agreement entitle Medivir to payments of up to a total of approximately USD 60 million, subject to the successful development and approval of remetinostat, in addition to future royalty payments in the mid-single-digit percentages of future net sales.